LT-002-158 clinical trials
LT-002-158 is named as an intervention in 3 current clinical trials in our China register. 3 are recruiting patients now. The most common phase is Phase 1/2. The lead sponsor is Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. The most-studied condition is Atopic Dermatitis (AD).
Patient leaflets for LT-002-158
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of LT-002-158
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Phase II Clinical Study to Evaluate the Efficacy and Safety of LT-002-158 Tablets in Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT07895615 · ClinicalTrials.gov ↗ · Atopic Dermatitis (AD)
|
Phase 2 | Recruiting | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd | China |
|
A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Subjects With Atopic Dermatitis
NCT06931990 · ClinicalTrials.gov ↗ · Atopic Dermatitis (AD)
|
Phase 1/2 | Recruiting | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd | China |
|
A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Patients With Hidradenitis Suppurativa
NCT06932003 · ClinicalTrials.gov ↗ · Hidradenitis Suppurativa (HS)
|
Phase 1/2 | Recruiting | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with LT-002-158
2 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Leadingtac Pharmaceutical (Shaoxing) Co., Ltd | 3 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 3 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about LT-002-158 trials
How many clinical trials are testing LT-002-158?
3 current trials in our China register name LT-002-158 as a drug or biological intervention, as of the registry sync on 11 November 2026. Completed and withdrawn studies are not counted.
Are LT-002-158 trials recruiting patients?
Yes. 3 of the 3 trials are recruiting: 3 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors LT-002-158 clinical trials?
The lead sponsor is Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how LT-002-158 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how LT-002-158 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists LT-002-158 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 11 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.